Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 325

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 325
---
| Net cash provided by/(used in) financing activities of the discontinued Opella business                                |                           |    -12 |      -4 |     -14 |
| Net cash provided by/(used in) financing activities                                                                    |                           | -5,763 |  -8,052 |  -5,821 |
| Impact of exchange rates on cash and cash equivalents                                                                  |                           |    -13 |     -32 |       8 |
| Impact on cash and cash equivalents of the reclassification of the Opella business to "Assets held for sale"           |                           |   -167 |       — |       — |
| Net change in cash and cash equivalents                                                                                |                           | -1,269 |  -4,026 |   2,638 |
| Cash and cash equivalents, beginning of period                                                                         |                           |  8,710 |  12,736 |  10,098 |
| Cash and cash equivalents, end of period                                                                               | D.13.                     |  7,441 |   8,710 |  12,736 |
| Cash and cash equivalents, beginning of period of discontinued operations reported as held for sale                    |                           |      — |       — |       — |
| Cash and cash equivalents, end of period of discontinued operations reported as held for sale                          |                           |    167 |       — |       — |

(a) Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations). (b) Includes non-current financial assets. (c) This line item includes contributions paid to pension funds (see Note D.19.1.). (d) This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional currencies and on instruments used to hedge such items.

| SANOFIFORM 20-F2024 | F-9 |

| 2024CONSOLIDATED FINANCIAL STATEMENTS |
| Consolidated statements of cash flows |

(e) Including:

|                                                    |   2024 |   2023 |   2022 |
| •Income tax paid                                   | -3,291 | -2,623 | -2,452 |
| •Interest paid                                     |   -587 |   -559 |   -380 |
| •Interest received                                 |    447 |    547 |    173 |
| •Dividends received from non-consolidated entities |